Long-term Angiogenesis Efficacy Using a Heparin-Conjugated Fibrin (HCF) Delivery System with HBM-MSCs.
- Author:
Ae Kyeong KIM
1
;
Min Hee KIM
;
Byung Soo KIM
;
Dong Ik KIM
Author Information
1. Division of Vascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. dikim@skku.edu
- Publication Type:Original Article
- Keywords:
Angiogenesis;
Ischemia;
Heparin-conjugated fibrin;
HBM-MSCs;
Vascular disease
- MeSH:
Angiogenesis Inducing Agents;
Animals;
Arterioles;
Capillaries;
Dogs;
Extremities;
Fibrin;
Humans;
Ischemia;
Mesenchymal Stromal Cells;
Muscles;
Transplants;
Vascular Diseases;
Vascular Endothelial Growth Factor A
- From:International Journal of Stem Cells
2012;5(1):23-30
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: Heparin-conjugated fibrin (HCF) is suitable for the release and localization of bFGF. We analyzed the effects of a bFGF delivery system using HCF with human bone marrow-derived mesenchymal stem cells (HBM- MSCs) in a dog ischemic limb model. METHODS AND RESULTS: Animals were divided into HBM-MSCs, HBM-MSCs+HCF, bFGF-HCF, and HBM-MSCs+bFGF-HCF groups. A total of 1x10(7) HBM-MSCs were injected per animal, and the amount of bFGF was 1 mg per dog. Ischemic muscles were harvested at eight weeks and six months after injection of cells. The HBM-MSCs+bFGF-HCF group exhibited decreased proportions of capillaries and arterioles six months after transplantation. However, there were more cells positive for the angiogenic factors, VEGF and PDGF, in the eight-week specimens compared with those harvested six months after transplantation. CONCLUSIONS: Our results demonstrated that a single injection of HBM-MSCs did not have significant long-term angiogenic effects; however, a bFGF delivery system using HCF exerted prolonged angiogenic effects when combined with HBM-MSCs.
